Dupilumab holds 70% biologic share across a $5B US market as JAK black-box warnings force second-line step-edit criteria at every major commercial payer.
Six agents are approved for moderate-to-severe atopic dermatitis in the US across two mechanism classes: four IL-4Rα biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and two oral JAK inhibitors (upadacitinib, abrocitinib). Dupilumab (Dupixent, Sanofi/Regeneron, approved 2017) holds approximately 70% of biologic prescriptions, backed by seven years of post-approval safety data and the broadest approved label. The addressable market is approximately 6.6 million US adults with moderate-to-severe disease.
The FDA's 2022 JAK inhibitor class black-box warning (covering malignancy, thrombosis, and major cardiovascular events) has created a two-tier formulary landscape. Major commercial payers (UHC, CVS/Aetna, Cigna) require prior biologic failure before approving JAK inhibitors, limiting upadacitinib and abrocitinib to second-line access despite superior short-term efficacy benchmarks. Pipeline agents targeting OX40/OX40L pathways (amlitelimab, rocatinlimab) represent the next competitive wave entering Phase 3 readout by 2025–2026.
Approved atopic dermatitis agents — United States, 2024
| Drug (Brand / INN) | Mechanism | Company | US Approval | Key Trial Result | Payer Routing |
|---|---|---|---|---|---|
| Dupixent (dupilumab) | IL-4Rα mAb SC | Sanofi / Regeneron | Mar 2017 | SOLO 1: IGA 0/1 38% vs 10% placebo | Part D; preferred tier; no black-box |
| Adbry (tralokinumab) | IL-13 mAb SC | LEO Pharma | Dec 2021 | ECZTRA 1: IGA 0/1 15.8% vs 7.1% placebo | Part D; non-preferred most payers |
| Rinvoq (upadacitinib) | JAK1 inhibitor oral | AbbVie | Jan 2022 | Measure Up 1: EASI-75 80% vs 16% placebo | Part D; prior biologic step-edit required |
| Cibinqo (abrocitinib) | JAK1 inhibitor oral | Pfizer | Jan 2022 | JADE MONO-1: IGA 0/1 44% vs 8% placebo | Part D; prior biologic step-edit required |
| Ebglyss (lebrikizumab) | IL-13 mAb SC | Eli Lilly | Sep 2023 | ADvocate 1: IGA 0/1 43.1% vs 12.7% placebo | Part D; formulary positioning forming |
Sources: FDA Drugs@FDA (approval dates); NEJM SOLO 1/2 (PMID 27690741); Lancet ECZTRA 1/2 (PMID 33000465); NEJM Measure Up 1/2 (PMID 34023008); NEJM JADE MONO-1 (PMID 32711801); NEJM ADvocate 1/2 (PMID 36920778); IQVIA prescription data 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Current PA language for upadacitinib and abrocitinib at UHC, CVS/Aetna, and Cigna • Prior biologic failure thresholds (trial duration, response criteria) by payer • Step-edit requirements comparing JAK vs biologic-naive and biologic-experienced pathways • Black-box warning impact on formulary tier positioning at commercial vs Medicare Part D
Delivers
- • Head-to-head data gap analysis: HEADS UP trial (dupilumab vs abrocitinib) key endpoints and limitations • FDA black-box label language for each JAK agent vs dupilumab's clean safety profile • Payer formulary tier positioning reflecting safety differentiation by plan type • KOL posture on JAK vs biologic sequencing in moderate-to-severe patients
Delivers
- • Phase 3 readout timelines and PDUFA dates for amlitelimab (OX40L), rocatinlimab (OX40), and cendakimab • Mechanism differentiation versus IL-4Rα class: positioning as biologic-naive or switch candidates • Commercial scenario modelling: step-edit placement vs dupilumab biosimilar entry timeline • Sanofi/Regeneron lifecycle management strategy for dupilumab
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why 6.6 million US adults with moderate-to-severe disease now choose among six approved agents split across two mechanism classes.
- How dupilumab's seven-year safety record helped it capture roughly 70% of biologic prescriptions among that population.
- Why Rinvoq's Measure Up 1 result, 80% EASI-75 versus 16% placebo, outperforms every other approved agent's headline trial data.
- How Dupixent's SOLO 1 result of 38% IGA 0/1 versus 10% placebo compares to newer entrants Adbry and Ebglyss.
- Why the FDA's 2022 black-box warning on malignancy, thrombosis, and cardiovascular events separates JAK inhibitors from IL-4Ra biologics.
- How four IL-4Ra biologics and two oral JAK inhibitors differ on route of administration, onset, and label safety language.
- Why UHC, CVS/Aetna, and Cigna all require documented biologic failure before approving upadacitinib or abrocitinib.
- How second-line step-edit placement persists for JAK inhibitors despite their superior short-term efficacy benchmarks versus biologics.
- Why Rinvoq and Cibinqo both carry mandatory prior-biologic step-edit requirements while Dupixent holds preferred-tier status.
- How Adbry's non-preferred placement at most payers contrasts with Ebglyss's still-forming formulary position.
- Why the HEADS UP trial comparing dupilumab head-to-head against abrocitinib remains central to prescriber sequencing decisions.
- How KOL posture on JAK versus biologic sequencing shapes prescribing in moderate-to-severe atopic dermatitis patients.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Atopic Dermatitis Competitive Intelligence sources: FDA Drugs@FDA (approval dates and labels), primary trial publications (NEJM, Lancet, JAMA Dermatology), ClinicalTrials.gov registrations, major commercial payer PA policy documents (UHC, CVS/Aetna, Cigna, Humana), and ICER Atopic Dermatitis Evidence Report 2023.
- Drug approval dates and label indications verified against FDA Drugs@FDA database
- Clinical trial results verified against published primary sources (NEJM, Lancet, JAMA Dermatology)
- PA and step-edit criteria verified against current UHC, CVS/Aetna, and Cigna coverage policy documents
- JAK inhibitor black-box warning language verified against FDA-approved prescribing information (2022 class update)
Frequently asked questions
Commission this brief
AXLRx delivers US Atopic Dermatitis competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.